Skip to content

Cognitive therapy for antenatal depression

A randomised controlled trial of cognitive therapy for antenatal depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN44902048
Enrollment
210
Registered
2010-02-17
Start date
2010-05-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression during pregnancy Pregnancy and Childbirth Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium

Interventions

Group 1 (Intervention arm plus usual care): Involvement in the study will last 33 weeks. Patients will be invited to attend up to 12 once weekly one-to-one CBT sessions, 60 minutes per sessions. Thes

Sponsors

University of Bristol (UK)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Pregnant women in North Bristol 2. Aged 16 or over 3. Between 8 and 18 weeks pregnant 4. Screen positive on the three question depression screen 5. Meet criteria for International Classification of Diseases, version 10 (ICD-10) depression (assessed using the Clinical Interview Schedule - Revised [CIS-R] version)

Exclusion criteria

Exclusion criteria: 1. Currently receiving CBT or another individual psychological therapy 2. Known to have a psychotic illness 3. Receiving care from secondary mental health services 4. Do not have sufficient English to complete questionnaires, as translation might affect the validity of the scales, and they would not be able to benefit from a talking therapy without an interpreter 5. Taking part in any other intervention trial

Design outcomes

Primary

MeasureTime frame
CIS-R diagnosis, conducted at baseline, 1st follow-up (15 weeks post-randomisation), and 2nd follow-up (33 weeks post-randomisation).

Secondary

MeasureTime frame
Other symptom measures (e.g. EPDS, PHQ-9, SF-12, EQ-5D), conducted at baseline, 1st follow-up (15 weeks post-randomisation), and 2nd follow-up (33 weeks post-randomisation).

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 24, 2026